Zusammenfassung
Die zentralen Probleme der Geburtsmedizin haben sich trotz der erweiterten medizinischen Erkenntnisse und der technischen Innovationen seit vielen Jahren nicht verändert. Nach wie vor stellen Frühgeburtlichkeit, Präeklampsie, fetale Wachstumsretardierung und fetale Fehlbildungen die klinisch tätigen Perinatologen vor große Herausforderungen. Da bei Erstkontakt mit der Klinik aufgrund der entsprechenden Schwangerschaftskomplikationen zeitlich meist keine grundlegende Therapie mehr möglich ist, fokussiert die heutige Schwangeren- und Geburtsmedizin auf eine individualisierte Präventionsstrategie. Diese richtet die Betreuung der Patientin an dem Risikoprofil der Schwangerschaft aus, das möglichst frühzeitig in der Schwangerschaft ermittelt wird. Durch neue Behandlungsansätze kann eine aktive Reduktion des individuellen Risikos erreicht werden.
Abstract
The core problems in prenatal medicine have not changed in recent years despite progress in medical knowledge and technical innovations. The challenges for obstetricians are still preterm birth, preeclampsia, intrauterine growth restriction and fetal anomalies. At the time when treatment in hospital due to these problems becomes necessary, a fundamental treatment is in most cases no longer possible; therefore, modern prenatal medicine focuses on an individualized preventive medicine strategy. For all of these problems it is possible to compute a patient-specific risk at the beginning of pregnancy that can be used to identify high risk patients who need intensive care treatment. New treatment strategies can help to lower the risk in this high risk group.
Literatur
Nicolaides KH (2011) Turning the pyramid of prenatal care. Fetal Diagn Ther 29:183–196
World Health Organization (2005) The World Health Report 2005: make every mother and child count (World Health Reports). World Health Organization, Geneva, S 252
Yu CK, Khouri O, Onwudiwe N et al (2008) Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 31:310–313
MacKay AP, Berg CJ, Atrash HK (2001) Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 97:533–538
Meads CA, Cnossen JS, Meher S et al (2008) Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12:iii–iv, 1–270
Papageorghiou AT, Yu CK, Bindra R et al (2001) Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 18:441–449
Onwudiwe N, Yu CK, Poon LCY et al (2008) Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol 32:877–883
Rumbold AR, Crowther CA, Haslam RR et al (2006) Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354:1796–1806
Poston L, Briley AL, Seed PT et a (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367:1145–1154
De-Regil LM, Palacios C, Ansary A et al (2012) Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2:CD008873
Hofmeyr GJ, Atallah AN, Duley L (2006) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev:CD001059
Bujold E, Roberge S, Lacasse Y et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116:402–414
Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32(Suppl):42–48
Akolekar R, Syngelaki A, Sarquis R et al (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31:66–74
Kagan KO, Wright D, Valencia C et al (2008) Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free-hCG and pregnancy-associated plasma protein-A. Hum Reprod 23:1968–1975
Stumm M, Entezami M, Trunk N et al (2012) Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. Prenat Diagn 32:569–577
Syngelaki A, Chelemen T, Dagklis T et al (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31:90–102
Hyett J, Perdu M, Sharland G et al (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318:81–85
Pereira S, Ganapathy R, Syngelaki A et al (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 117:1384–1391
Chaoui R, Nicolaides KH (2010) From nuchal translucency to intracranial translucency: towards the early detection of spina bifida. Ultrasound Obstet Gynecol 35:133–138
Bartlett LA, Berg CJ, Shulman HB et al (2004) Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 103:729–737
Honest H, Forbes CA, Durée KH et al (2009) Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 13:1–627
Celik E, To M, Gajewska K et al (2008) Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound Obstet Gynecol 31:549–554
Vergnes J-N, Sixou M (2007) Preterm low birth weight and maternal periodontal status: a meta-analysis. Am J Obstet Gynecol 196:135.e1–e7
Greco E, Gupta R, Syngelaki A et al (2012) First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 31:154–161
Greco E, Lange A, Ushakov F et al (2010) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31:84–89
Czeizel AE, Dudás I, Métneki J (1994) Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report. Arch Gynecol Obstet 255:131–139
Saling E, Schreiber M (2005) Laktobazillen-Schutzsystem bei Schwangeren – effiziente Vermeidung von Frühgeburten durch Früherkennung von Störungen. Z Geburtshilfe Neonatol 209:128–134
Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group (2001) Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 357:989–994
Lumley J, Chamberlain C, Dowswell T et al (2009) Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev:CD001055
Fonseca EB, Celik E, Parra M et al (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469
Hassan SS, Romero R, Vidyadhari D et al (2011) Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38:18–31
Goya M, Pratcorona L, Merced C et al (2012) Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet 379:1800–1806
Berghella V, Rafael TJ, Szychowski JM et al (2011) Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 117:663–671
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kagan, K., Hoopmann, M., Abele, H. et al. Zukünftige Entwicklung der Geburtsmedizin. Gynäkologe 45, 684–689 (2012). https://doi.org/10.1007/s00129-012-2964-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-012-2964-2